{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T19:01:02Z","timestamp":1786993262195,"version":"build-2736575974"},"reference-count":113,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,5,18]],"date-time":"2021-05-18T00:00:00Z","timestamp":1621296000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005865","name":"Mochida Memorial Foundation for Medical and Pharmaceutical Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005865","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007449","name":"Takeda Science Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007449","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmacological Sciences"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1016\/j.jphs.2021.05.002","type":"journal-article","created":{"date-parts":[[2021,5,24]],"date-time":"2021-05-24T04:29:35Z","timestamp":1621830575000},"page":"33-39","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"title":["Resolvins as potential candidates for the treatment of major depressive disorder"],"prefix":"10.1016","volume":"147","author":[{"given":"Satoshi","family":"Deyama","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masabumi","family":"Minami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsuyuki","family":"Kaneda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jphs.2021.05.002_bib1","series-title":"Depression fact sheets","author":"World Health Organization","year":"2020"},{"key":"10.1016\/j.jphs.2021.05.002_bib2","doi-asserted-by":"crossref","first-page":"155","DOI":"10.4088\/JCP.14m09298","article-title":"The economic burden of adults with major depressive disorder in the United States (2005 and 2010)","volume":"76","author":"Greenberg","year":"2015","journal-title":"J\u00a0Clin Psychiatr"},{"key":"10.1016\/j.jphs.2021.05.002_bib3","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1001\/jama.292.3.338","article-title":"Antidepressants and the risk of suicidal behaviors","volume":"292","author":"Jick","year":"2004","journal-title":"J\u00a0Am Med Assoc"},{"key":"10.1016\/j.jphs.2021.05.002_bib4","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1176\/appi.ajp.163.1.28","article-title":"Evaluation of outcomes with citalopram for depression using measurement-based care in STAR\u2217D: implications for clinical practice","volume":"163","author":"Trivedi","year":"2006","journal-title":"Am J Psychiatr"},{"key":"10.1016\/j.jphs.2021.05.002_bib5","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/S0006-3223(99)00230-9","article-title":"Antidepressant effects of ketamine in depressed patients","volume":"47","author":"Berman","year":"2000","journal-title":"Biol Psychiatr"},{"key":"10.1016\/j.jphs.2021.05.002_bib6","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1001\/archpsyc.63.8.856","article-title":"A\u00a0randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression","volume":"63","author":"Zarate","year":"2006","journal-title":"Arch Gen Psychiatr"},{"key":"10.1016\/j.jphs.2021.05.002_bib7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1056\/NEJMp1903305","article-title":"Esketamine for treatment-resistant depression - first FDA-approved antidepressant in a new class","volume":"381","author":"Kim","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jphs.2021.05.002_bib8","doi-asserted-by":"crossref","first-page":"l7069","DOI":"10.1136\/bmj.l7069","article-title":"Esketamine is approved in Europe for treating resistant major depressive disorder","volume":"367","author":"Mahase","year":"2019","journal-title":"BMJ"},{"key":"10.1016\/j.jphs.2021.05.002_bib9","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S2215-0366(17)30272-9","article-title":"Side-effects associated with ketamine use in depression: a systematic review","volume":"5","author":"Short","year":"2018","journal-title":"Lancet Psychiatry"},{"key":"10.1016\/j.jphs.2021.05.002_bib10","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.biopsych.2015.10.018","article-title":"Intravenous esketamine in adult treatment-resistant depression: a double-blind, double-randomization, placebo-controlled study","volume":"80","author":"Singh","year":"2016","journal-title":"Biol Psychiatr"},{"key":"10.1016\/j.jphs.2021.05.002_bib11","doi-asserted-by":"crossref","first-page":"e632","DOI":"10.1038\/tp.2015.136","article-title":"R-ketamine: a rapid-onset and sustained antidepressant without psychotomimetic side effects","volume":"5","author":"Yang","year":"2015","journal-title":"Transl Psychiatry"},{"key":"10.1016\/j.jphs.2021.05.002_bib12","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1038\/nature13479","article-title":"Pro-resolving lipid mediators are leads for resolution physiology","volume":"510","author":"Serhan","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.jphs.2021.05.002_bib13","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1093\/ijnp\/pyx023","article-title":"Resolvin D1 and D2 reverse lipopolysaccharide-induced depression-like behaviors through the mTORC1 signaling pathway","volume":"20","author":"Deyama","year":"2017","journal-title":"Int J Neuropsychopharmacol"},{"key":"10.1016\/j.jphs.2021.05.002_bib14","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.jphs.2018.09.006","article-title":"Resolvin E3 attenuates lipopolysaccharide-induced depression-like behavior in mice","volume":"138","author":"Deyama","year":"2018","journal-title":"J\u00a0Pharmacol Sci"},{"key":"10.1016\/j.jphs.2021.05.002_bib15","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/s00213-017-4774-7","article-title":"Resolvin E1\/E2 ameliorate lipopolysaccharide-induced depression-like behaviors via ChemR23","volume":"235","author":"Deyama","year":"2018","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.jphs.2021.05.002_bib16","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.bbr.2017.06.010","article-title":"Rapid and sustained antidepressant effects of resolvin D1 and D2 in a chronic unpredictable stress model","volume":"332","author":"Ishikawa","year":"2017","journal-title":"Behav Brain Res"},{"key":"10.1016\/j.jphs.2021.05.002_bib17","doi-asserted-by":"crossref","first-page":"172837","DOI":"10.1016\/j.pbb.2019.172837","article-title":"Neurotrophic mechanisms underlying the rapid and sustained antidepressant actions of ketamine","volume":"188","author":"Deyama","year":"2020","journal-title":"Pharmacol Biochem Behav"},{"key":"10.1016\/j.jphs.2021.05.002_bib18","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1111\/ejn.14630","article-title":"Role of BDNF in the pathophysiology and treatment of depression: activity-dependent effects distinguish rapid-acting antidepressants","volume":"53","author":"Duman","year":"2021","journal-title":"Eur J Neurosci"},{"key":"10.1016\/j.jphs.2021.05.002_bib19","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1038\/nm.4050","article-title":"Synaptic plasticity and depression: new insights from stress and rapid-acting antidepressants","volume":"22","author":"Duman","year":"2016","journal-title":"Nat Med"},{"key":"10.1016\/j.jphs.2021.05.002_bib20","doi-asserted-by":"crossref","first-page":"2921","DOI":"10.1523\/JNEUROSCI.17-08-02921.1997","article-title":"Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex","volume":"17","author":"Moghaddam","year":"1997","journal-title":"J\u00a0Neurosci"},{"key":"10.1016\/j.jphs.2021.05.002_bib21","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.biopsych.2007.05.028","article-title":"Cellular mechanisms underlying the antidepressant effects of ketamine: role of alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors","volume":"63","author":"Maeng","year":"2008","journal-title":"Biol Psychiatr"},{"key":"10.1016\/j.jphs.2021.05.002_bib22","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1172\/JCI130808","article-title":"GABA interneurons are the cellular trigger for ketamine's rapid antidepressant actions","volume":"130","author":"Gerhard","year":"2020","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.jphs.2021.05.002_bib23","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.biopsych.2018.12.014","article-title":"Neurotrophic and antidepressant actions of brain-derived neurotrophic factor require vascular endothelial growth factor","volume":"86","author":"Deyama","year":"2019","journal-title":"Biol Psychiatr"},{"key":"10.1016\/j.jphs.2021.05.002_bib24","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1176\/appi.ajp.2018.17121368","article-title":"Role of neuronal VEGF signaling in the prefrontal cortex in the rapid antidepressant effects of ketamine","volume":"176","author":"Deyama","year":"2019","journal-title":"Am J Psychiatr"},{"key":"10.1016\/j.jphs.2021.05.002_bib25","doi-asserted-by":"crossref","first-page":"pyu033","DOI":"10.1093\/ijnp\/pyu033","article-title":"BDNF release is required for the behavioral actions of ketamine","volume":"18","author":"Lepack","year":"2014","journal-title":"Int J Neuropsychopharmacol"},{"key":"10.1016\/j.jphs.2021.05.002_bib26","doi-asserted-by":"crossref","first-page":"112844","DOI":"10.1016\/j.bbr.2020.112844","article-title":"The duration of the antidepressant-like effects of a single infusion of brain-derived neurotrophic factor into the medial prefrontal cortex in mice","volume":"394","author":"Deyama","year":"2020","journal-title":"Behav Brain Res"},{"key":"10.1016\/j.jphs.2021.05.002_bib27","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/j.cellsig.2007.12.009","article-title":"Vascular endothelial growth factor (VEGF) signaling regulates hippocampal neurons by elevation of intracellular calcium and activation of calcium\/calmodulin protein kinase II and mammalian target of rapamycin","volume":"20","author":"Kim","year":"2008","journal-title":"Cell Signal"},{"key":"10.1016\/j.jphs.2021.05.002_bib28","doi-asserted-by":"crossref","first-page":"9760","DOI":"10.1523\/JNEUROSCI.1427-04.2004","article-title":"Brain-derived neurotrophic factor induces mammalian target of rapamycin-dependent local activation of translation machinery and protein synthesis in neuronal dendrites","volume":"24","author":"Takei","year":"2004","journal-title":"J\u00a0Neurosci"},{"key":"10.1016\/j.jphs.2021.05.002_bib29","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1126\/science.1190287","article-title":"mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists","volume":"329","author":"Li","year":"2010","journal-title":"Science"},{"key":"10.1016\/j.jphs.2021.05.002_bib30","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1016\/j.biopsych.2011.09.030","article-title":"Brain-derived neurotrophic factor Val66Met\u00a0allele impairs basal and ketamine-stimulated synaptogenesis in prefrontal cortex","volume":"71","author":"Liu","year":"2012","journal-title":"Biol Psychiatr"},{"key":"10.1016\/j.jphs.2021.05.002_bib31","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/nature10130","article-title":"NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses","volume":"475","author":"Autry","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.jphs.2021.05.002_bib32","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1016\/j.bbadis.2016.04.001","article-title":"Hippocampal VEGF is necessary for antidepressant-like behaviors but not sufficient for antidepressant-like effects of ketamine in rats","volume":"1862","author":"Choi","year":"2016","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.jphs.2021.05.002_bib33","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.biopsych.2017.06.017","article-title":"Activity-dependent brain-derived neurotrophic factor release is required for the rapid antidepressant actions of scopolamine","volume":"83","author":"Ghosal","year":"2018","journal-title":"Biol Psychiatr"},{"key":"10.1016\/j.jphs.2021.05.002_bib34","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1016\/j.biopsych.2013.04.025","article-title":"Scopolamine rapidly increases mammalian target of rapamycin complex 1 signaling, synaptogenesis, and antidepressant behavioral responses","volume":"74","author":"Voleti","year":"2013","journal-title":"Biol Psychiatr"},{"key":"10.1016\/j.jphs.2021.05.002_bib35","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1038\/npp.2016.202","article-title":"GLYX-13 produces rapid antidepressant responses with key synaptic and behavioral effects distinct from ketamine","volume":"42","author":"Liu","year":"2017","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.jphs.2021.05.002_bib36","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1038\/mp.2017.220","article-title":"BDNF release and signaling are required for the antidepressant actions of GLYX-13","volume":"23","author":"Kato","year":"2018","journal-title":"Mol Psychiatr"},{"key":"10.1016\/j.jphs.2021.05.002_bib37","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1073\/pnas.1814709116","article-title":"Activity-dependent brain-derived neurotrophic factor signaling is required for the antidepressant actions of (2R,6R)-hydroxynorketamine","volume":"116","author":"Fukumoto","year":"2019","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jphs.2021.05.002_bib38","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1038\/s41398-019-0624-1","article-title":"Molecular and cellular mechanisms underlying the antidepressant effects of ketamine enantiomers and its metabolites","volume":"9","author":"Yang","year":"2019","journal-title":"Transl Psychiatry"},{"key":"10.1016\/j.jphs.2021.05.002_bib39","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1038\/nature17998","article-title":"NMDAR inhibition-independent antidepressant actions of ketamine metabolites","volume":"533","author":"Zanos","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.jphs.2021.05.002_bib40","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1007\/s00406-020-01110-5","article-title":"Intravenous arketamine for treatment-resistant depression: open-label pilot study","volume":"271","author":"Leal","year":"2021","journal-title":"Eur Arch Psychiatr Clin Neurosci"},{"key":"10.1016\/j.jphs.2021.05.002_bib41","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/j.drudis.2018.11.007","article-title":"A\u00a0new generation of antidepressants: an update on the pharmaceutical pipeline for novel and rapid-acting therapeutics in mood disorders based on glutamate\/GABA neurotransmitter systems","volume":"24","author":"Wilkinson","year":"2019","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.jphs.2021.05.002_bib42","series-title":"Relmada Therapeutics announces top-line results from REL-1017 phase 2 study in individuals with treatment resistant depression","author":"Therapeutics","year":"2019"},{"key":"10.1016\/j.jphs.2021.05.002_bib43","series-title":"Relmada Therapeutics announces initiation of second pivotal phase 3 study of REL-1017 as adjunctive treatment for patients with major depressive disorder","author":"Therapeutics","year":"2021"},{"key":"10.1016\/j.jphs.2021.05.002_bib44","doi-asserted-by":"crossref","first-page":"E1","DOI":"10.1038\/nature22084","article-title":"Effects of a ketamine metabolite on synaptic NMDAR function","volume":"546","author":"Suzuki","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.jphs.2021.05.002_bib45","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1124\/mol.120.119784","article-title":"Hydroxynorketamine blocks N-methyl-D-aspartate receptor cuurents by binding to closed receptors","volume":"98","author":"Abbott","year":"2020","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.jphs.2021.05.002_bib46","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1016\/j.cell.2021.01.034","article-title":"Antidepressant drugs act by directly binding to TRKB neurotrophin receptors","volume":"184","author":"Casarotto","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.jphs.2021.05.002_bib47","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.biopsych.2017.05.016","article-title":"Mechanistic target of rapamycin-independent antidepressant effects of (R)-ketamine in a social defeat stress model","volume":"83","author":"Yang","year":"2018","journal-title":"Biol Psychiatr"},{"key":"10.1016\/j.jphs.2021.05.002_bib48","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/s41586-020-03047-0","article-title":"Antidepressant actions of ketamine engage cell-specific translocation via elF4E","volume":"590","author":"Aguilar-Valles","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.jphs.2021.05.002_bib49","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1038\/s41386-020-0644-9","article-title":"Modulation of the antidepressant effects of ketamine by the mTORC1 inhibitor rapamycin","volume":"45","author":"Abdallah","year":"2020","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.jphs.2021.05.002_bib50","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1176\/appi.ajp.2011.11010128","article-title":"Monitoring ketamine treatment response in a depressed patient via peripheral mammalian target of rapamycin activation","volume":"168","author":"Denk","year":"2011","journal-title":"Am J Psychiatr"},{"key":"10.1016\/j.jphs.2021.05.002_bib51","doi-asserted-by":"crossref","first-page":"e35","DOI":"10.1016\/j.biopsych.2012.07.022","article-title":"Acute increases in plasma mammalian target of rapamycin, glycogen synthase kinase-3\u03b2, and eukaryotic elongation factor 2 phosphorylation after ketamine treatment in three depressed patients","volume":"73","author":"Yang","year":"2013","journal-title":"Biol Psychiatr"},{"key":"10.1016\/j.jphs.2021.05.002_bib52","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1016\/j.pnpbp.2011.05.010","article-title":"The mTOR signaling pathway in the prefrontal cortex is compromised in major depressive disorder","volume":"35","author":"Jernigan","year":"2011","journal-title":"Prog Neuro-Psychopharmacol Biol Psychiatry"},{"key":"10.1016\/j.jphs.2021.05.002_bib53","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1172\/JCI126859","article-title":"Sestrin modulator NV-5138 produces rapid antidepressant effects via direct mTORC1 activation","volume":"129","author":"Kato","year":"2019","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.jphs.2021.05.002_bib54","series-title":"Navitor's three phase 1 studies for NV-5138 show antidepressant effects and biomarker impact, supporting further development of direct activator of mTORC1 in depression","author":"Navitor","year":"2019"},{"key":"10.1016\/j.jphs.2021.05.002_bib55","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1038\/s41398-019-0515-5","article-title":"Efficacy of omega-3 PUFAs in depression: a meta-analysis","volume":"9","author":"Liao","year":"2019","journal-title":"Transl Psychiatry"},{"key":"10.1016\/j.jphs.2021.05.002_bib56","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.3390\/nu13041070","article-title":"Effects of n-3 polyunsaturated fatty acid supplementation in the prevention and treatment of depressive disorders\u2013a systematic review and meta-analysis","volume":"13","author":"Wolters","year":"2021","journal-title":"Nutrients"},{"key":"10.1016\/j.jphs.2021.05.002_bib57","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1159\/000502652","article-title":"International Society for Nutritional Psychiatry Research practice guidelines for omega-3 fatty acids in the treatment of major depressive disorder","volume":"88","author":"Guu","year":"2019","journal-title":"Psychother Psychosom"},{"key":"10.1016\/j.jphs.2021.05.002_bib58","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1176\/ajp.2006.163.6.1098","article-title":"Omega-3 treatment of childhood depression: a controlled, double-blind pilot study","volume":"163","author":"Nemets","year":"2006","journal-title":"Am J Psychiatr"},{"key":"10.1016\/j.jphs.2021.05.002_bib59","doi-asserted-by":"crossref","first-page":"644","DOI":"10.4088\/JCP.v69n0418","article-title":"Omega-3 fatty acids for major depressive disorder during pregnancy: results from a randomized, double-blind, placebo-controlled trial","volume":"69","author":"Su","year":"2008","journal-title":"J\u00a0Clin Psychiatr"},{"key":"10.1016\/j.jphs.2021.05.002_bib60","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1038\/s41398-020-00886-3","article-title":"The efficacy and safety of omega-3 fatty acids on depressive symptoms in perinatal women: a meta-analysis of randomized placebo-controlled trials","volume":"10","author":"Zhang","year":"2020","journal-title":"Transl Psychiatry"},{"key":"10.1016\/j.jphs.2021.05.002_bib61","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.biopsych.2004.11.038","article-title":"Antidepressant-like effects of uridine and omega-3 fatty acids are potentiated by combined treatment in rats","volume":"57","author":"Carlezon","year":"2005","journal-title":"Biol Psychiatr"},{"key":"10.1016\/j.jphs.2021.05.002_bib62","doi-asserted-by":"crossref","first-page":"e437","DOI":"10.1038\/tp.2014.77","article-title":"Nutritional omega-3 modulates neuronal morphology in the prefrontal cortex along with depression-related behaviour through corticosterone secretion","volume":"4","author":"Larrieu","year":"2014","journal-title":"Transl Psychiatry"},{"key":"10.1016\/j.jphs.2021.05.002_bib63","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.psyneuen.2008.08.025","article-title":"PUFA induce antidepressant-like effects in parallel to structural and molecular changes in the hippocampus","volume":"34","author":"Venna","year":"2009","journal-title":"Psychoneuroendocrinology"},{"key":"10.1016\/j.jphs.2021.05.002_bib64","doi-asserted-by":"crossref","first-page":"3860","DOI":"10.1007\/s12035-020-01980-9","article-title":"N-3 PUFA have antidepressant-like effects via improvement of the HPA-axis and neurotransmission in rats exposed to combined stress","volume":"57","author":"Kim","year":"2020","journal-title":"Mol Neurobiol"},{"key":"10.1016\/j.jphs.2021.05.002_bib65","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1038\/nrn.2016.69","article-title":"Integrating neuroimmune systems in the neurobiology of depression","volume":"17","author":"Wohleb","year":"2016","journal-title":"Nat Rev Neurosci"},{"key":"10.1016\/j.jphs.2021.05.002_bib66","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1111\/ejn.14720","article-title":"Neuroinflammation and depression: a review","volume":"53","author":"Troubat","year":"2021","journal-title":"Eur J Neurosci"},{"key":"10.1016\/j.jphs.2021.05.002_bib67","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1007\/s00394-016-1373-z","article-title":"Fish oil supplementation attenuates neuroinflammation and alleviates depressive-like behavior in rats submitted to repeated lipopolysaccharide","volume":"57","author":"Dang","year":"2018","journal-title":"Eur J Nutr"},{"key":"10.1016\/j.jphs.2021.05.002_bib68","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1080\/10253890410001667188","article-title":"Dietary ethyl-eicosapentaenoic acid but not soybean oil reverses central interleukin-1-induced changes in behavior, corticosterone and immune response in rats","volume":"7","author":"Song","year":"2004","journal-title":"Stress"},{"key":"10.1016\/j.jphs.2021.05.002_bib69","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/j.biopsych.2014.01.008","article-title":"Omega-3 fatty acids in the prevention of interferon-alpha-induced depression: results from a randomized, controlled trial","volume":"76","author":"Su","year":"2014","journal-title":"Biol Psychiatr"},{"key":"10.1016\/j.jphs.2021.05.002_bib70","doi-asserted-by":"crossref","first-page":"18050","DOI":"10.1038\/s41598-018-36679-4","article-title":"Identification of specialized pro-resolving mediator clusters from healthy adults after intravenous low-dose endotoxin and omega-3 supplementation: a methodological validation","volume":"8","author":"Norris","year":"2018","journal-title":"Sci Rep"},{"key":"10.1016\/j.jphs.2021.05.002_bib71","doi-asserted-by":"crossref","first-page":"102219","DOI":"10.1016\/j.plefa.2020.102219","article-title":"Dose- and time-dependent increase in circulating anti-inflammatory and pro-resolving lipid mediators following eicosapentaenoic acid supplementation in patients with major depressive disorder and chronic inflammation","volume":"164","author":"Lamon-Fava","year":"2021","journal-title":"Prostaglandins Leukot Essent Fatty Acids"},{"key":"10.1016\/j.jphs.2021.05.002_bib72","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1073\/pnas.0907342107","article-title":"Resolvin D1 binds human phagocytes with evidence for proresolving receptors","volume":"107","author":"Krishnamoorthy","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jphs.2021.05.002_bib73","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/1471-2164-10-24","article-title":"The G protein-coupled receptor subset of the dog genome is more similar to that in humans than rodents","volume":"10","author":"Haitina","year":"2009","journal-title":"BMC Genom"},{"key":"10.1016\/j.jphs.2021.05.002_bib74","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1084\/jem.20150225","article-title":"Identification of resolvin D2 receptor mediating resolution of infections and organ protection","volume":"212","author":"Chiang","year":"2015","journal-title":"J\u00a0Exp Med"},{"key":"10.1016\/j.jphs.2021.05.002_bib75","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/j.bbrc.2006.06.175","article-title":"Identification of N-arachidonylglycine as the endogenous ligand for orphan G-protein-coupled receptor GPR18","volume":"347","author":"Kohno","year":"2006","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.jphs.2021.05.002_bib76","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/1471-2202-11-44","article-title":"N-arachidonoyl glycine, an abundant endogenous lipid, potently drives directed cellular migration through GPR18, the putative abnormal cannabidiol receptor","volume":"11","author":"McHugh","year":"2010","journal-title":"BMC Neurosci"},{"key":"10.1016\/j.jphs.2021.05.002_bib77","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1084\/jem.20042031","article-title":"Stereochemical assignment, antiinflammatory properties, and receptor for the omega-3 lipid mediator resolvin E1","volume":"201","author":"Arita","year":"2005","journal-title":"J\u00a0Exp Med"},{"key":"10.1016\/j.jphs.2021.05.002_bib78","doi-asserted-by":"crossref","first-page":"3912","DOI":"10.4049\/jimmunol.178.6.3912","article-title":"Resolvin E1 selectively interacts with leukotriene B4 receptor BLT1 and ChemR23 to regulate inflammation","volume":"178","author":"Arita","year":"2007","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.jphs.2021.05.002_bib79","doi-asserted-by":"crossref","first-page":"4527","DOI":"10.4049\/jimmunol.1103652","article-title":"Resolvin E2 formation and impact in inflammation resolution","volume":"188","author":"Oh","year":"2012","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.jphs.2021.05.002_bib80","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.coph.2013.05.012","article-title":"Resolution phase lipid mediators of inflammation: agonists of resolution","volume":"13","author":"Serhan","year":"2013","journal-title":"Curr Opin Pharmacol"},{"key":"10.1016\/j.jphs.2021.05.002_bib81","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.neulet.2012.06.075","article-title":"Chronic mild restraint stress rats decreased CMKLR1 expression in distinct brain region","volume":"524","author":"Guo","year":"2012","journal-title":"Neurosci Lett"},{"key":"10.1016\/j.jphs.2021.05.002_bib82","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1007\/s11064-018-2573-0","article-title":"Localisation of formyl-peptide receptor 2 in the rat central nervous system and its role in axonal and dendritic outgrowth","volume":"43","author":"Ho","year":"2018","journal-title":"Neurochem Res"},{"key":"10.1016\/j.jphs.2021.05.002_bib83","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.brainres.2016.10.006","article-title":"Expression and cell distribution of leukotriene B4 receptor 1 in the rat brain cortex after experimental subarachnoid hemorrhage","volume":"1652","author":"Ye","year":"2016","journal-title":"Brain Res"},{"key":"10.1016\/j.jphs.2021.05.002_bib84","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s13041-018-0351-1","article-title":"Resolvin D2 protects against cerebral ischemia\/reperfusion injury in rats","volume":"11","author":"Zuo","year":"2018","journal-title":"Mol Brain"},{"key":"10.1016\/j.jphs.2021.05.002_bib85","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1111\/bpa.12812","article-title":"Receptors for pro-resolving mediators are increased in Alzheimer's disease brain","volume":"30","author":"Emre","year":"2020","journal-title":"Brain Pathol"},{"key":"10.1016\/j.jphs.2021.05.002_bib86","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.jalz.2013.12.024","article-title":"Resolution of inflammation is altered in Alzheimer's disease","volume":"11","author":"Wang","year":"2015","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.jphs.2021.05.002_bib87","doi-asserted-by":"crossref","first-page":"C1331","DOI":"10.1152\/ajpcell.00207.2011","article-title":"Resolvin D1 prevents TNF-alpha-mediated disruption of salivary epithelial formation","volume":"302","author":"Odusanwo","year":"2012","journal-title":"Am J Physiol Cell Physiol"},{"key":"10.1016\/j.jphs.2021.05.002_bib88","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1038\/mi.2016.33","article-title":"Lipoxin A4 activates ALX\/FPR2 receptor to regulate conjunctival goblet cell secretion","volume":"10","author":"Hodges","year":"2017","journal-title":"Mucosal Immunol"},{"key":"10.1016\/j.jphs.2021.05.002_bib89","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1080\/15548627.2015.1078958","article-title":"Activation of autophagy in macrophages by pro-resolving lipid mediators","volume":"11","author":"Prieto","year":"2015","journal-title":"Autophagy"},{"key":"10.1016\/j.jphs.2021.05.002_bib90","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.arcmed.2020.05.002","article-title":"Resolvin D1 ameliorates nicotinamide-streptozotocin-induced type 2 diabetes mellitus by its anti-inflammatory action and modulating PI3K\/Akt\/mTOR pathway in the brain","volume":"51","author":"Bathina","year":"2020","journal-title":"Arch Med Res"},{"key":"10.1016\/j.jphs.2021.05.002_bib91","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1124\/jpet.114.216036","article-title":"Neuronal nitric oxide synthase-dependent elevation in adiponectin in the rostral ventrolateral medulla underlies g protein-coupled receptor 18-mediated hypotension in conscious rats","volume":"351","author":"Penumarti","year":"2014","journal-title":"J\u00a0Pharmacol Exp Therapeut"},{"key":"10.1016\/j.jphs.2021.05.002_bib92","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1016\/j.jid.2018.03.1498","article-title":"Biosynthesis of D-series resolvins in skin provides insights into their role in tissue repair","volume":"138","author":"Hellmann","year":"2018","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.jphs.2021.05.002_bib93","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1002\/jcp.25918","article-title":"Gax suppresses chemerin\/CMKLR1-induced preadipocyte biofunctions through the inhibition of Akt\/mTOR and ERK signaling pathways","volume":"233","author":"Jiang","year":"2018","journal-title":"J\u00a0Cell Physiol"},{"key":"10.1016\/j.jphs.2021.05.002_bib94","doi-asserted-by":"crossref","first-page":"3451","DOI":"10.1074\/jbc.M109.044131","article-title":"Resolvin E1 receptor activation signals phosphorylation and phagocytosis","volume":"285","author":"Ohira","year":"2010","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.jphs.2021.05.002_bib95","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.neuropharm.2014.05.043","article-title":"Effects of D-series resolvins on behavioral and neurochemical changes in a fibromyalgia-like model in mice","volume":"86","author":"Klein","year":"2014","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.jphs.2021.05.002_bib96","doi-asserted-by":"crossref","first-page":"5396","DOI":"10.3390\/md12115396","article-title":"Resolvin D1, a metabolite of omega-3 polyunsaturated fatty acid, decreases post-myocardial infarct depression","volume":"12","author":"Gilbert","year":"2014","journal-title":"Mar Drugs"},{"key":"10.1016\/j.jphs.2021.05.002_bib97","doi-asserted-by":"crossref","first-page":"2597","DOI":"10.4049\/jimmunol.1201272","article-title":"Resolvin D1 and resolvin D2 govern local inflammatory tone in obese fat","volume":"189","author":"Claria","year":"2012","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.jphs.2021.05.002_bib98","doi-asserted-by":"crossref","first-page":"9323","DOI":"10.1074\/jbc.M609212200","article-title":"Resolvin D1 and its aspirin-triggered 17R epimer. Stereochemical assignments, anti-inflammatory properties, and enzymatic inactivation","volume":"282","author":"Sun","year":"2007","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.jphs.2021.05.002_bib99","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1007\/s12035-017-0413-x","article-title":"Distribution of Alox15 in the rat brain and its role in prefrontal cortical resolvin D1 formation and spatial working memory","volume":"55","author":"Shalini","year":"2018","journal-title":"Mol Neurobiol"},{"key":"10.1016\/j.jphs.2021.05.002_bib100","doi-asserted-by":"crossref","first-page":"12750","DOI":"10.1096\/fj.201900283R","article-title":"Resolvin E3 attenuates allergic airway inflammation via the interleukin-23-interleukin-17A pathway","volume":"33","author":"Sato","year":"2019","journal-title":"Faseb J"},{"key":"10.1016\/j.jphs.2021.05.002_bib101","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1021\/ar200024c","article-title":"Free radical oxidation of polyunsaturated lipids: new mechanistic insights and the development of peroxyl radical clocks","volume":"44","author":"Pratt","year":"2011","journal-title":"Acc Chem Res"},{"key":"10.1016\/j.jphs.2021.05.002_bib102","doi-asserted-by":"crossref","first-page":"5944","DOI":"10.1021\/cr200084z","article-title":"Free radical lipid peroxidation: mechanisms and analysis","volume":"111","author":"Yin","year":"2011","journal-title":"Chem Rev"},{"key":"10.1016\/j.jphs.2021.05.002_bib103","doi-asserted-by":"crossref","first-page":"22847","DOI":"10.1074\/jbc.M603766200","article-title":"Metabolic inactivation of resolvin E1 and stabilization of its anti-inflammatory actions","volume":"281","author":"Arita","year":"2006","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.jphs.2021.05.002_bib104","doi-asserted-by":"crossref","first-page":"L904","DOI":"10.1152\/ajplung.00370.2014","article-title":"Proresolving actions of a new resolvin D1 analog mimetic qualifies as an immunoresolvent","volume":"308","author":"Orr","year":"2015","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"10.1016\/j.jphs.2021.05.002_bib105","doi-asserted-by":"crossref","first-page":"6224","DOI":"10.1021\/acs.orglett.6b02612","article-title":"Design and synthesis of cyclopropane congeners of resolvin E2, an endogenous proresolving lipid mediator, as its stable equivalents","volume":"18","author":"Fukuda","year":"2016","journal-title":"Org Lett"},{"key":"10.1016\/j.jphs.2021.05.002_bib106","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1021\/acsmedchemlett.9b00596","article-title":"Design and synthesis of benzene congeners of resolvin E2, a proresolving lipid mediator, as its stable equivalents","volume":"11","author":"Murakami","year":"2020","journal-title":"ACS Med Chem Lett"},{"key":"10.1016\/j.jphs.2021.05.002_bib107","doi-asserted-by":"crossref","first-page":"30697","DOI":"10.1074\/jbc.M115.679068","article-title":"Untargeted plasma metabolomics identifies endogenous metabolite with drug-like properties in chronic animal model of multiple sclerosis","volume":"290","author":"Poisson","year":"2015","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.jphs.2021.05.002_bib108","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1002\/glia.23779","article-title":"RvE1 treatment prevents memory loss and neuroinflammation in the Ts65Dn mouse model of Down syndrome","volume":"68","author":"Hamlett","year":"2020","journal-title":"Glia"},{"key":"10.1016\/j.jphs.2021.05.002_bib109","doi-asserted-by":"crossref","first-page":"3945","DOI":"10.1038\/s41467-019-11928-w","article-title":"Blunting neuroinflammation with resolvin D1 prevents early pathology in a rat model of Parkinson's disease","volume":"10","author":"Krashia","year":"2019","journal-title":"Nat Commun"},{"key":"10.1016\/j.jphs.2021.05.002_bib110","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0055859","article-title":"Proresolution lipid mediators in multiple sclerosis - differential, disease severity-dependent synthesis - a clinical pilot trial","volume":"8","author":"Pr\u00fcss","year":"2013","journal-title":"PloS One"},{"key":"10.1016\/j.jphs.2021.05.002_bib111","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1080\/08039488.2019.1673480","article-title":"Resolvin D1 as a novel anti-inflammatory marker in manic, depressive and euthymic states of bipolar disorder","volume":"74","author":"Kok Kendirlioglu","year":"2020","journal-title":"Nord J Psychiatr"},{"key":"10.1016\/j.jphs.2021.05.002_bib112","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1038\/nature05877","article-title":"Resolvin E1 and protectin D1 activate inflammation-resolution programmes","volume":"447","author":"Schwab","year":"2007","journal-title":"Nature"},{"key":"10.1016\/j.jphs.2021.05.002_bib113","doi-asserted-by":"crossref","first-page":"14983","DOI":"10.1073\/pnas.1206641109","article-title":"Resolvin E1 promotes phagocytosis-induced neutrophil apoptosis and accelerates resolution of pulmonary inflammation","volume":"109","author":"El Kebir","year":"2012","journal-title":"Proc Natl Acad Sci U S A"}],"container-title":["Journal of Pharmacological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S134786132100044X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S134786132100044X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T20:01:17Z","timestamp":1761163277000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S134786132100044X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9]]},"references-count":113,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["S134786132100044X"],"URL":"https:\/\/doi.org\/10.1016\/j.jphs.2021.05.002","relation":{},"ISSN":["1347-8613"],"issn-type":[{"value":"1347-8613","type":"print"}],"subject":[],"published":{"date-parts":[[2021,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Resolvins as potential candidates for the treatment of major depressive disorder","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmacological Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jphs.2021.05.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Production and hosting by Elsevier B.V. on behalf of Japanese Pharmacological Society.","name":"copyright","label":"Copyright"}]}}